Aurobindo Pharma Seals EU Biosimilars Deal with STADA, Gets FDA Update

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Aurobindo Pharma Seals EU Biosimilars Deal with STADA, Gets FDA Update
Overview

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has agreed to a marketing and distribution deal with European company STADA Arzneimittel AG for two EMA-approved biosimilars in select EU markets. This partnership enters Aurobindo into the fast-growing European biosimilars sector. Separately, Aurobindo's Apitoria Pharma subsidiary received a Voluntary Action Indicated (VAI) classification from the USFDA for its Unit-V facility, indicating a closed inspection without immediate enforcement actions. Aurobindo Pharma shares closed higher on the news.

EU Partnership Boosts Biosimilar Reach

Aurobindo Pharma is set to expand its presence in the European Union's biosimilars market through a significant marketing and distribution agreement with STADA Arzneimittel AG. The pact involves Aurobindo's subsidiary, CuraTeQ Biologics, partnering with the European firm for two EMA-approved biosimilars. This move targets key EU markets and taps into a sector projected for strong growth. The agreement leverages STADA's established distribution network to enhance CuraTeQ's market penetration. The European biosimilars market is a substantial growth area, estimated at $16.2 billion in 2025 and expected to grow at a compound annual growth rate (CAGR) of approximately 15.75% through 2034. This strategic alignment positions Aurobindo to capture a significant share of this expanding segment. The news coincided with a slight increase in Aurobindo Pharma's stock, which closed at ₹1,308.00 on March 25, 2026, up 2.09%.

CuraTeQ's Pipeline and STADA's Strength

CuraTeQ Biologics, Aurobindo's subsidiary, focuses on biosimilars in oncology and immunology. It holds EMA approvals for Dyrupeg (pegfilgrastim) and Zefylti (filgrastim), as well as MHRA approval for Bevqolva (bevacizumab) and a positive EMA opinion for Dazublys (trastuzumab). The EMA's approval process, which relies on comparability studies, helps facilitate market entry for these complex products. STADA Arzneimittel AG, a major player in European healthcare, reported €4,296 million in group sales for fiscal year 2025. Its specialty pharma segment has seen double-digit growth in biosimilar sales, and the company has a history of successful biosimilar collaborations. The European biosimilar market's expansion is partly driven by significant cost savings, estimated to have exceeded €50 billion for healthcare systems since 2006.

US FDA Inspection Update

In parallel with the EU expansion, Aurobindo Pharma received an update from the US Food and Drug Administration (USFDA). The company's Apitoria Pharma subsidiary's Unit-V facility in India concluded its inspection with a Voluntary Action Indicated (VAI) classification. This classification means the inspection is closed, and no immediate enforcement actions are required by the FDA. This development contrasts with an 'Official Action Indicated' (OAI) status previously issued to its subsidiary Eugia Pharma Specialities Ltd. for its Unit-II facility, which typically signals issues that require regulatory attention. While past VAI classifications have been met with positive market reactions, a pattern of mixed inspection outcomes across manufacturing sites can present compliance challenges. Consistent adherence to regulatory standards is crucial in the highly competitive global biosimilar market.

Analyst Outlook

Looking ahead, analysts maintain a generally positive outlook for Aurobindo Pharma. The consensus rating is 'Moderate Buy,' with an average 12-month price target around ₹1,385.00. JM Financial Institutional Securities reiterated a BUY rating and a target of ₹1,610, projecting significant revenue, EBITDA, and PAT growth (CAGRs of 17%, 21%, and 26% respectively) between FY26 and FY28. They consider the stock undervalued compared to industry peers. Aurobindo's strategic focus on higher-return segments like biosimilars, along with recent acquisitions, is expected to drive improvements in its return on invested capital and potentially lead to a re-rating of its valuation.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.